Table 4 Factors associated with the continuation of sustained remission
Variable | Sustained remission continued (n = 22) | Flare (n = 7) | P value |
|---|---|---|---|
Female, n (%) | 18 (81.9) | 6 (85.7) | 0.81 |
Age, years | 49.8 ± 14.2 (52) | 54.4 ± 23.9 (63) | 0.33 |
Weight, kg | 55.0 ± 9.5 (53) | 47.9 ± 8.3 (46) | 0.99 |
Disease duration, years | 3.6 ± 4.5 (1.8) | 9.2 ± 11.3 (2) | 0.15 |
Time until achievement of remission | 3.8 ± 3.3 (3) | 2.0 ± 1.9 (1) | 0.13 |
DAS28-ESR at baseline | 3.97 ± 0.96 (3.73) | 4.19 ± 0.56 (4.13) | 0.41 |
DAS28-ESR at achievement of remission | 1.85 ± 0.44 (1.96) | 2.25 ± 0.43 (2.42) | 0.027 |
RF-positive, n (%) | 12 (54.6) | 4 (57.1) | 0.90 |
ACPA-positive, n (%) | 13 (61.9) | 4 (66.7) | 0.83 |
Presence of bone erosion, n (%) | 12 (57.1) | 5 (71.4) | 0.50 |
HAQ-DI at baseline | 0.18 ± 0.36 (0) | 0.52 ± 1.11 (0) | 0.69 |
HAQ-DI at achievement of remission | 0.23 ± 0.40 (0) | 0.54 ± 1.06 (0) | 0.76 |
MTX at baseline, mg/week | 10.8 ± 3.01 (10) | 12.5 ± 3.45 (12.5) | 0.21 |
MTX at achievement of remission, mg/week | 10.6 ± 2.79 (10) | 12.0 ± 3.00 (12) | 0.26 |
Oral steroid use, n (%) | 3 (13.6) | 2 (28.6) | 0.36 |
Prior use of biologics, n (%) | 3 (13.6) | 0 (0) | 0.30 |
Observation period, months | 27.8 ± 18.6 (20.5) | 32.4 ± 21.4 (23.0) | 0.54 |